262368-48-9

Basic information

• Product Name: 4-[2-(4-methylpiperazin-1-yl)ethyl]aniline
• Synonyms: 4-[2-(4-methylpiperazin-1-yl)ethyl]aniline;[4-[2-(4-METHYLPIPERAZIN-1-YL)ETHYL]PHENYL]AMINE;OTAVA-BB 1036666
• CAS NO: 262368-48-9
• Molecular Formula: C₁₃H₂₁N₃
• Molecular Weight: 219.33
• Mol File: 262368-48-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 353.8°C at 760 mmHg
• Flash Point: 165.3°C
• Appearance: /
• Density: 1.048g/cm³
• Vapor Pressure: 3.51E-05mmHg at 25°C
• Refractive Index: 1.567
• CAS DataBase Reference: 4-[2-(4-methylpiperazin-1-yl)ethyl]aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[2-(4-methylpiperazin-1-yl)ethyl]aniline(262368-48-9)
• EPA Substance Registry System: 4-[2-(4-methylpiperazin-1-yl)ethyl]aniline(262368-48-9)

Safety Data

• Hazardous Substances Data: 262368-48-9(Hazardous Substances Data)

Usage

General Description

4-[2-(4-methylpiperazin-1-yl)ethyl]aniline, also known as Meclizine, is an antihistamine and anticholinergic medication that is commonly used to treat motion sickness and dizziness. It works by blocking the action of histamine in the body, which helps to alleviate symptoms of nausea, vomiting, and vertigo. Meclizine is a member of the piperazine class of antihistamines and has a chemical structure that includes an aniline group and a piperazine ring. It is often found in over-the-counter medications and may also be prescribed by doctors to help manage symptoms of various vestibular disorders and inner ear problems. While generally considered safe for most individuals, Meclizine may cause drowsiness and other side effects in some people, so it is important to use it as directed and consult a healthcare professional before beginning treatment.

InChI:InChI=1/C13H21N3/c1-15-8-10-16(11-9-15)7-6-12-2-4-13(14)5-3-12/h2-5H,6-11,14H2,1H3

Upstream product

• 851651-79-1 1-methyl-4-[2-(4-nitro-phenyl)-ethyl]-piperazine 

Downstream Products

• 928788-76-5 8-indan-5-yl-2-{4-[2-(4-methylpiperazin-1-yl)-ethyl]phenylamino}-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 
• 1395028-60-0 6-(2,6-dichlorophenyl)-2-({4-[2-(4-methylpiperazin-1-yl)ethyl]phenyl}amino)imidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one 
• 1023276-77-8 8-(4-ethynyl-phenyl)-2-{4-[2-(4-methyl-piperazin-1-yl)-ethyl]-phenylamino}-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 
• 1023276-78-9 8-cyclohexyl-2-{4-[2-(4-methyl-piperazin-1-yl)-ethyl]-phenylamino}-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 
• 936929-86-1 2-[2-hydroxy-5-(2-methoxy-pyridin-3-yl)-phenyl]-7-methyl-3H-benzimidazole-5-carboxylic acid {4-[2-(4-methyl-piperazin-1-yl)-ethyl]-phenyl}-amide 
• 936939-63-8 2-amino-N-{4-[2-(4-methyl-piperazin-1-yl)-ethyl]-phenyl}-3-nitro-benzamide 
• 936935-78-3 5-amino-1-(8-methoxy-5,6-dihydro-benzo[h]quinazolin-2-yl)-1H-pyrazole-4-carboxylic acid {4-[2-(4-methyl-piperazin-1-yl)-ethyl]-phenyl}-amide 

Relevant articles and documents

COMPOUNDS

A compound of formula (I): compositions and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity.

5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase

The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein: W, A, Y, Z, R101 and R200 are described in the specification.

2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES

The present invention relates to pyrimidine or pyridine carbamate compounds having the general Formula (1) and pharmaceutically acceptable salts or derivatives thereof. Also included are methods of treatment of various diseases and conditions, including inflammation, inhibition of T cell activation and proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, the methods comprising administering a therapeutically-effective amount a compound of Formula I, or a salt or derivative form thereof, as described above.